Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 17:11:564925.
doi: 10.3389/fimmu.2020.564925. eCollection 2020.

Immunopathogenesis of COVID-19: Summary and Possible Interventions

Affiliations
Review

Immunopathogenesis of COVID-19: Summary and Possible Interventions

Francois Henri Jacques et al. Front Immunol. .

Abstract

Since the onset of the COVID-19 pandemic in the fall of 2019 over 4 million people have been infected and over 280,000 have died (1). Information about the SARS-CoV2 virus is evolving rapidly. At this time there are no interventions proven to be effective for cases infected with SARS-CoV2. Current knowledge about the clinical and laboratory manifestations of COVID-19 infection is reviewed and combined with knowledge about the immunopathogenic mechanisms of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV1) and Middle East Respiratory Syndrome (MERS) to formulate theories and suggest possible therapeutic interventions. SARS-CoV2 immunopathogenic mechanisms vary from immunosuppression that initially enables viral escape to a hyperinflammatory immune response. Ultimately therapeutic intervention will be phase dependent.

Keywords: COVID-19; hyperinflammation; immunology; immunosuppression; intervention.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
COVID 19 Links between immunosuppression and hyperinflammation.

Similar articles

Cited by

References

    1. Johns Hopkins Coronavirus Resource Center. COVID-19 Map [Internet]. Johns Hopkins Coronavirus Resource Center. (2020). Available online at: https://coronavirus.jhu.edu/map.html (accessed May 11, 2020).
    1. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surv Bull Eur Sur Mal Transm Eur Commun Dis Bull. (2020) 25:2000180. - PMC - PubMed
    1. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. (2020) 26:453–5. 10.1038/s41591-020-0819-2 - DOI - PMC - PubMed
    1. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of t cells in patients with coronavirus disease 2019 (COVID-19). medRxiv. (2020). [Preprint]. 10.1101/2020.02.18.20024364 - DOI - PMC - PubMed
    1. Schönrich G, Raftery MJ. The PD-1/PD-L1 Axis and virus infections: a delicate balance. Front Cell Infect Microbiol. (2019) 9:207. - PMC - PubMed